Onco Wiki / Capacidad de acción

FLT3-F691L is a gatekeeper mutation arising under FLT3-TKI selective pressure (gilteritin...

Vista determinista de la entidad fuente YAML. La autoridad clínica sigue con los ID de fuente citados y estado de firma del revisor.

IDBMA-FLT3-F691L-AML
TipoRelevancia terapéutica
Situaciónreviewed 2026-04-27 | pending_clinical_signoff | actionability review required
EnfermedadesDIS-AML
FuentesSRC-ADMIRAL-PERL-2019 SRC-CIVIC SRC-ELN-AML-2022

Hechos relativos a la posibilidad de adoptar medidas

BiomarcadorBIO-FLT3-D835
VarianteMutación de resistencia del portero F691L (post-FLT3i)
EnfermedadDIS-AML
El nivel de ESCATIIA
Combinaciones recomendadassalvage chemo + allo-SCT (preferred when fit), clinical trial (next-gen FLT3i, crenolanib, FF-10101), venetoclax + azacitidine (off-label salvage)
Monoterapia contraindicadagilteritinib (resistencia cruzada F691L), quizartinib(resistencia transversal F691)
Resumen de las pruebasFLT3-F691L is a gatekeeper mutation arising under FLT3-TKI selective pressure (gilteritinib, quizartinib). Confers cross-resistance to most current FLT3i. Crenolanib (investigational type-I) and next-gen FLT3i retain partial activity. No approved targeted option — clinical trial enrollment or salvage chemo + allo-SCT.

Notas

ESCAT IIA (resistance biomarker — guides what NOT to use). OncoKB Level R1. Cell intentionally uses BIO-FLT3-D835 as biomarker_id because F691L is a TKD/kinase-domain mutation captured under the FLT3-D835 / TKD entity per the cherry-picked BIO file (no separate F691L biomarker). variant_qualifier disambiguates. Clinical use: trigger ctDNA / BM rebiopsy at gilteritinib failure to detect F691L vs D835 emergence.

Utilizado por

Relevancia terapéutica